Chunk #22 — PRECLINICAL DRUG DEVELOPMENT

Source: Glutamatergic transmission in schizophrenia: from basic research to clinical practice.
Embedded: yes

Text

In addition to ongoing clinical development of glycine-site agonists and glycine transport inhibitors, several novel mechanisms for enhancement of NMDA function are currently under preclinical development.